Standard of Care: Inhalers and Step-Therapy

For decades, asthma treatment relied on two separate tools: a “controller” to prevent symptoms and a “rescue” (SABA) inhaler for quick relief. However, international guidelines from the Global Initiative for Asthma (GINA) have fundamentally shifted this approach ^[1].

The modern standard of care for allergic asthma moves away from using rescue inhalers alone. Instead, it prioritizes putting a small dose of anti-inflammatory medicine into your lungs every time you feel a symptom ^[2].

The End of SABA-Only Treatment

In the past, many patients with “mild” asthma were prescribed only a SABA (Short-Acting Beta-Agonist), such as albuterol. Current guidelines now discourage this ^[1].

While a SABA quickly opens your airways, it does nothing to treat the underlying inflammation ^[2]. Relying only on a SABA leaves you at risk for severe exacerbations; frequent SABA use is associated with higher exacerbation risk and does not treat airway inflammation ^[3][2]. Today, the recommendation is that nearly every adult and adolescent with asthma should use an ICS (Inhaled Corticosteroid) to treat that inflammation ^[1].

The MART Strategy: One Inhaler, Two Roles

The preferred approach for many patients is called MART (Maintenance and Reliever Therapy), sometimes also called SMART ^[4]. This strategy uses a single inhaler containing both an ICS (for inflammation) and formoterol (a Long-Acting Beta-Agonist that starts working as fast as a rescue inhaler) ^[5].

• How it works: You use the inhaler once or twice a day as your regular maintenance dose. If you feel a flare-up or “tightness,” you use the same inhaler as your rescue puff ^[4]. (Note: At lower steps of care, some patients use an as-needed low-dose ICS-formoterol inhaler for relief without scheduled maintenance).
• The Benefit: This ensures that whenever your symptoms increase, you automatically receive an extra “boost” of anti-inflammatory medicine right when you need it most ^[4].
• Proven Results: Research shows that anti-inflammatory reliever strategies like MART significantly reduce exacerbation risk in appropriate populations compared to traditional therapies ^[6].

Warning: MART is not appropriate with every ICS-LABA combination. Only specific rapid-onset ICS-formoterol products (like budesonide-formoterol) are used this way. Products containing salmeterol cannot be used as a reliever. The specific product, age group, regulatory approval, and maximum daily inhalations are regimen-specific. You must follow your individualized plan ^[4].

Moving Up the Steps: Add-on Treatments

If your asthma remains uncontrolled on a standard ICS-formoterol or ICS-LABA combination, your doctor may suggest “stepping up” your treatment by adding a third medication:

LAMA (Long-Acting Muscarinic Antagonist)

A LAMA (such as tiotropium) is a different type of bronchodilator that helps keep the airways open for 24 hours ^[7]. It is typically added as a “triple therapy” (ICS + LABA + LAMA) when a patient continues to have frequent symptoms or flare-ups despite being on a high-dose controller ^[8]. While LAMAs are effective at improving overall lung function, they are always used in addition to your steroid inhaler, never as a replacement ^[9].

LTRA (Leukotriene Receptor Antagonist)

An LTRA, such as montelukast, is a daily pill that blocks leukotrienes—chemicals your body releases during an allergic reaction ^[10].

• Role: These are often used as an alternative or add-on for patients who also have hay fever (allergic rhinitis) ^[10].
• Safety Note: Montelukast carries a prominent neuropsychiatric warning in several jurisdictions, including reports of nightmares, depression, suicidal thoughts or behavior, and other serious behavior changes. Explain the benefit–risk discussion with your doctor, seek urgent help for suicidal thoughts or severe behavior changes, and note that its use for mild allergic rhinitis is restricted or discouraged in some jurisdictions ^[11].

Treating the Root Cause: Immunotherapy

For those with allergic asthma specifically driven by triggers like house dust mites, Allergen Immunotherapy (AIT) offers a way to retrain the immune system ^[12].

• SCIT (Subcutaneous Immunotherapy): Often called “allergy shots,” these involve regular injections of a tiny amount of the allergen to build tolerance ^[13].
• SLIT (Sublingual Immunotherapy): This involves a daily tablet placed under the tongue. For house dust mites, SLIT has been shown to reduce the need for inhaled corticosteroids in adults and adolescents with well-controlled asthma ^[12][14]. (Note: Unstandardized “drops” are not interchangeable with approved tablets).

Allergen immunotherapy is an adjunct for carefully selected patients with a relevant exposure. Your asthma must be clinically controlled before starting, as uncontrolled or severe asthma increases the risk of systemic reactions. SCIT injections and the first dose of an approved SLIT product require product- and jurisdiction-specific medical supervision. It does not replace your ICS, and you should never reduce controller therapy without the treating clinician’s direction ^[12][15].